Company news

Keros Therapeutics, Inc. news in 2022

Keros Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

December 11, 2022

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

November 6, 2022

Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047

November 2, 2022

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

November 2, 2022

Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

September 11, 2022

Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Keros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting

September 5, 2022

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

August 3, 2022

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

June 12, 2022

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association

June 9, 2022

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

May 17, 2022

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

May 16, 2022

Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

May 11, 2022

Keros Therapeutics Reports First Quarter 2022 Financial Results

May 4, 2022

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

March 8, 2022

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer

January 30, 2022

Decks in 2022